Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

Barişta I., Tekuzman G., Yalçin Ş., Güllü I., Güler N., Özişik Y., ...More

Journal of Surgical Oncology, vol.73, no.1, pp.12-16, 2000 (SCI-Expanded, Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 1
  • Publication Date: 2000
  • Journal Name: Journal of Surgical Oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.12-16
  • Keywords: doxorubicin, ifosfamide, soft tissue sarcoma, HIGH-DOSE IFOSFAMIDE, ADVANCED REFRACTORY SARCOMAS, PHASE-II TRIAL, PLUS DOXORUBICIN, EUROPEAN-ORGANIZATION, ADRIAMYCIN, MESNA, ADULT, BONE, INFUSION
  • Lokman Hekim University Affiliated: No

Abstract

Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m2/day as 72-hour continuous infusion with mesna at the same dosage and schedule. Doxorubicin was given at the dose of 60 mg/m2/day as 2-hour infusion on day 1. Six patients had a complete response (15%), and 9 (22.5%) had a partial response, fourteen patients (35%) stable disease, and 11 (27.5%) did not respond to chemotherapy. The median duration of response was 13 and 5 months for the complete and partial responders, respectively. The median survival was 37 months. Febrile neutropenia was encountered in 9 cases (22.5%). The present ifosfamide and doxorubicin combination is a moderately effective and well- tolerable regimen in the treatment of advanced soft tissue sarcomas.